Parker Institute for Cancer Immunotherapy – PICI shared a post on LinkedIn:
“Excited to share new research from PICI Center Director Jedd Wolchok, PICI researchers Taha Merghoub, Mohamad Hamieh, and other researchers from Weill Cornell Medicine, where they highlight a promising new approach to treating bladder cancer.
Published in the Journal of Experimental Medicine, the study identifies MUC16 as a promising target for CAR T cell therapy and demonstrates that delivering CAR T cells directly into the bladder effectively controls tumors in preclinical models while minimizing systemic toxicity.
These findings could help pave the way for new bladder-sparing treatment options for patients with therapy-resistant disease.”
Title: Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models
Authors: Parwiz Abrahimi, Jonathan Khan, Alyssa Duren-Lubanski, Winson Cai, Yacine Marouf, Nan Chen, Daniel Hirschhorn, Renata Mammone, Ileana Miranda, Jacob Tallman, Alejandra Vela-Moreno, Mohamad Hamieh, Bishoy Faltas, Thomas Carroll, Micaela Everitt, Hari Subramanian, Hikmat Al-Ahmadie, Olivier Elemento, Benjamin Hopkins, Douglas Scherr, Renier Brentjens, Jedd Wolchok, Taha Merghoub
Read the Full Article on Journal of Experimental Medicine
Other articles about Parker Institute for Cancer Immunotherapy on OncoDaily.